Login
$WST
$417.41 +$0.99 (0.24%) Live

$WST 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance

26 Oct 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

EXECUTION VERSION Credit Agreement - West Pharma (2026) (Conformed Signatures for 8-K Filing)(24019362844.2) - 10/26/2026 3:26:03 PM Deal CUSIP Number: 95530RAH2 Revolver A: 95530RAJ8 Revolver B: 95530RAL3 Term A Facility: 95530RAK5 CRED...

23 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.

14 Jul 2026 8-K: Entry into a Material Definitive Agreement

West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship A...

01 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) dated as of May 31, 2026 (the “Effective Date”) is entered by and between West Pharmaceutical Services, Inc., a Pennsylvania corporation (the “Company...

11 May 2026 8-K: Material Cybersecurity Incidents; Regulation FD Disclosure

West is committed to providing timely and transparent communication to all stakeholders regarding the recent cyberattack on its network systems. Following initial detection of an intrusion on May 4, 2026, West Pharmaceutical Services pro...

05 May 2026 8-K: Submission of Matters to a Vote of Security Holders

West Pharmaceutical Services, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026. The four proposals that were voted on at the Annual Meeting are described in detail in the Company’s 2026 Proxy Sta...

23 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

–Strong Start to the Year and Raising Full Year Revenue and EPS guidance

09 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Investor Contact: Media Contact: John Sweeney, CFA Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-484-790-0373 +1-610-594-3054 [email protected] [email protected] Eric...

12 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components –

23 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

- Delivered solid growth across Proprietary Products and Contract Manufacturing Segments -

11 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Today, September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay ...

24 Jul 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Exton, PA, July 24, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend.

21 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

530 Herman O. West Drive ● Exton, PA 19341 July 11, 2025 Robert McMahon (Sent via email) RE: Offer Letter – Senior Vice President and Chief Financial Officer Dear Robert: I am pleased to offer you the position of Senior Vice President an...

08 May 2025 8-K: Submission of Matters to a Vote of Security Holders

AMENDED AND RESTATED ARTICLES OF INCORPORATION OF WEST PHARMACEUTICAL SERVICES, INC. (Effective as of May 6, 2025) 1. The name of the Corporation is West Pharmaceutical Services, Inc. 2. The location and post office address of the Corpor...

24 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

530 Herman O. West Drive ● Exton, PA 19341 March 28, 2025 Mr. Shane Campbell (Sent via email) RE: Offer Letter – SVP, Chief Proprietary Segment Officer Dear Shane: I am pleased to offer you the position of Senior Vice President and Chief...

24 Apr 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

14 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release Agreement (“Agreement”) is entered into between CINDY REISS-CLARK (“you”) and West Pharmaceutical Services, Inc. (“Company”). You and the Company (tog...

11 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day. As part of this transition, her ...

13 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Exton, PA, February 13, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support